Our partner is committed to the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer.

This critical hire determined and oversaw research and development and overall strategic direction of the company. They represented high value programs to Executive Leadership and the Board of Directors, led all clinical development based in the US, partnered with overseas partners, and continued to develop promising combination immuno-oncology programs with internal and partnered assets. This highly influential leader utilized strategic collaborations to increase the organization’s pipeline of assets, explore new treatment areas, and advance oncology programs to broaden patient populations.